Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …

Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …

PARP inhibitors (PARPi), a cancer therapy targeting poly (ADP-ribose) polymerase, are the
first clinically approved drugs designed to exploit synthetic lethality, a genetic concept …

Abstract Approximately 1–5% of breast cancers are attributed to inherited mutations in
BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) …

Fanconi anemia (FA) is a complex genetic disorder characterized by bone marrow failure
(BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer …

Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …

Germline aberrations in critical DNA-repair and DNA damage–response (DDR) genes
cause cancer predisposition, whereas various tumors harbor somatic mutations causing …

Pancreatic cancer remains one of the most lethal of malignancies and a major health
burden. We performed whole-genome sequencing and copy number variation (CNV) …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …